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A B S T R A C T
Aquaculture is one of the world's most important and fastest growing food production sectors, with an average
annual growth of 5.8% during the period 2001–2016. Common carp (Cyprinus carpio) is one of the main aquatic
species produced for human consumption and is the world's third most produced finfish. Koi carp, on the other
hand, are grown as a popular ornamental fish. In the late 1990s, both of these sectors were threatened by the
emergence of a deadly disease caused by cyprinid herpesvirus 3 (CyHV-3; initially called koi herpesvirus or
KHV). Since then, several research groups have focused their work on developing methods to fight this disease.
Despite increasing knowledge about the pathobiology of this virus, there are currently no efficient and cost-
effective therapeutic methods available to fight this disease. Facing the lack of efficient treatments, safe and
efficacious prophylactic methods such as the use of vaccines represent the most promising approach to the
control of this virus. The common carp production sector is not a heavily industrialized production sector and
the fish produced have low individual value. Therefore, development of vaccine methods adapted to mass
vaccination are more suitable. Multiple vaccine candidates against CyHV-3 have been developed and studied,
including DNA, bacterial vector, inactivated, conventional attenuated and recombinant attenuated vaccines.
However, there is currently only one vaccine commercially available in limited regions. The present review aims
to summarize and evaluate the knowledge acquired from the study of these vaccines against CyHV-3 and provide
discussion on future prospects.
1. Introduction
Aquaculture is one of the world's most important and fastest growing
food production sectors, with an average annual growth of 5.8% during
the period 2001–2016 [1]. Common carp (Cyprinus carpio) is one of the
main aquatic species produced for human consumption. It is currently
the world's 3rd most produced finfish, accounting for around 8% of the
global production. As of 2016, annual production of common carp has
reached 4.6 million tons [1]. Koi carp, on the other hand, are grown as a
popular ornamental fish, kept in personal ponds by hobbyists, or
sometimes submitted to koi competitions and exhibitions. In the late
1990s, both of these sectors were threatened by the emergence of a
deadly disease caused by cyprinid herpesvirus 3 (CyHV-3) (genus
Cyprinivirus, family Alloherpesviridae, order Herpesvirales), initially called
koi herpesvirus (KHV), or carp interstitial nephritis and gill necrosis virus
(CNGV) [2–4]. Notably, the World Organisation for Animal Health (OIE)
has listed CyHV-3 as a notifiable disease [5].
Since then, several research groups have focused their work on
developing methods to fight this disease. One such method takes ad-
vantage of the fact that CyHV-3 replication and disease is strongly
correlated with water temperature, with the disease occurring mainly at
water temperatures between 18 and 28 °C [2]. This observation has
been exploited for the treatment of CyHV-3 infection by moving en-
vironmental temperatures at a suboptimal or non-permissive tempera-
ture for viral replication (>30 °C). This method was also used as a
natural immunization method [6]. Unfortunately, fish infected through
this approach were only partially protected against a subsequent chal-
lenge [6,7] and could potentially become latently infected by CyHV-3.
Recently, fish infected by CyHV-3 have been shown to naturally seek
out warmer environments which increases their ability to control
CyHV-3 infection. This response to infection is known as behavioural
fever [8]. This property could be exploited in aquaculture. Despite in-
creasing knowledge about the pathobiology of this virus, there is cur-
rently no rational, efficient and cost-effective therapeutic methods
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available to fight this disease.
Facing the lack of efficient treatment, safe and efficacious prophylactic
methods such as the use of vaccines represent the most promising approach
in controlling this virus. In order to be feasible, vaccination of fish should
ideally involve delivery methods adapted to the mass vaccination of the
target species – thus minimizing the cost for vaccination. They should also
stimulate long-lasting adaptive immunity, ideally over the entire lifetime of
fish, and facilitate inoculation at earliest immunocompetent developmental
stages. This is particularly true in the context of the common carp pro-
duction sector that is not heavily industrialized and where fish produced
have low individual value. Multiple vaccine candidates against CyHV-3
have been studied and currently only one is commercially available in a
limited number of regions (Table 1). The present review aims to
summarize the knowledge acquired from studies involving development
of vaccines against CyHV-3. Future prospects on CyHV-3 vaccine are
briefly discussed throughout the review and will be developed in the last
section of this manuscript.
2. Genomic and biologic comparison of CyHV-3 strains
To date, the full-length genome sequences of 11 cell culture isolated
CyHV-3 strains from different geographical origins have been published
[9–11]. Genomic comparisons of these strains revealed a high level of
similarity (>99% identity). This high degree of sequence similarity was
confirmed by comparing full-length genome sequences of CyHV-3 ob-
tained directly from infected fish tissues using targeted viral genomic
enrichment [12]. Despite the high degree of genome sequence simi-
larity, phylogenetic analysis of CyHV-3 full-length genome sequences
revealed the existence of two major genetic lineages, initially named
European and Asian [11]. Interestingly, analysis of one isolated strain
(CyHV-3 GZ11), suggested the existence of a third, as of yet undetected,
lineage, highlighting that future discoveries are likely regarding CyHV-3
diversity. Furthermore, the same study is the only example of com-
parative study of genomic and biological data from different CyHV-3
strains [11]. Importantly, the comparison of virulence among these
strains lead to the identification of low, moderate and high virulence
strains. Inter-lineage polymorphisms do not explain the differences of
virulence observed, i.e. low and high virulence strains were found in
both lineages [11]. Of note, a negative correlation was observed be-
tween the viral growth in vitro and the virulence in vivo inferring that,
in general, the more adapted a viral strain is to cell culture, the more
attenuated it is in vivo. This was the case for the highly cell culture-
adapted CyHV-3 T strain [13]. The apparent low genomic diversity
found among CyHV-3 strains can be considered as an advantage in
terms of vaccine development. Indeed, cross protection following
vaccination is expected but has not been studied, with the exception of
a single report [14]. More importantly, the difference in virulence
found among CyHV-3 strains, likely the consequence of cell culture,
highlights the importance of selecting the correct strains for the
development of vaccine. This selection applies at the beginning of the
development when selecting the parental strain that will be used to
produce the attenuated strain, and later when selecting a challenge
strain to test the efficacy of the vaccine developed.
3. Epidemiological status of CyHV-3
There are limited published reports on the epidemiological data
related to CyHV-3 prevalence and disease. Until now, CyHV-3 has been
identified in at least 26 countries worldwide, including Israel, USA,
China, Japan, and Indonesia [2]. CyHV-3 has not been reported in
Africa (with the exception of South Africa), South America and Aus-
tralia. Since its emergence in the late 1990s, CyHV-3 has caused mass
outbreaks in carp in both natural environments and in fish farms. Initial
outbreaks in Israel were responsible for annual losses estimated to US$
3 million [15]. Similarly, early outbreaks in Indonesia (2002, 2003)
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M. Boutier, et al. Fish and Shellfish Immunology 93 (2019) 531–541
533
introduced into a specific environment, CyHV-3 can be maintained over
consecutive seasons or years. This was demonstrated both in carp farms
[16], but also in natural environment [17,18]. Nowadays, the exact
epidemiological status and economical consequences of CyHV-3 infec-
tions and outbreaks are not clearly known and require further study.
4. Types of vaccines studied
4.1. DNA vaccines
DNA vaccines consist of genetically engineered DNA plasmids or
fragments encoding for specific antigens from pathogens. They have
different practical advantages, plasmid DNA vaccines are produced in
prokaryotic cells, yielding large amounts of highly pure and stable
DNA. However, DNA vaccines usually require injections into the fish in
order to achieve adequate immune protection, although the oral route
has been successfully used in few trials [19]. In terms of CyHV-3 DNA
vaccines, early reports have investigated the potential use of expression
plasmids encoding ORF81 and ORF25 glycoproteins (a major envelope
protein, and a member of the ORF25 glycoprotein family, respectively).
In these trials, three successive injections of different doses of DNA
(1 μg, 10 μg and 50 μg per 250 g carp) led to a serological response and
immune protection (Relative Percent Survival (RPS) of around 80%)
(Table 2) [20,21]. Similarly, the CyHV-3 glycoprotein ORF25 was
tested in combination with the carp interleukin-1β (IL-1β) cytokine
gene as a prototypic adjuvanted DNA vaccine. Following inoculation, it
was found that, while the co-expression of IL-1β can enhance the ser-
ological immune response, it had no statistically significant effect on
the protection observed (RPS of 85% and 75%, with or without the
IL-1β adjuvant, respectively) [22]. Very recently, another study has
investigated the practical use of an ORF25 DNA vaccine with the aim of
optimizing vaccine delivery through the oral route. Surprisingly, they
found that intra-muscular (IM) injection of the CyHV-3 ORF25 DNA
construct (fused with the green fluorescent protein (GFP)) protects fish
against a lethal challenge by immersion, but not by cohabitation (RPS
89% against 26%, respectively) [23]. This result highlights the im-
portance of using relevant challenge methods for assessing vaccine ef-
ficacy. Notably previous reports on the ORF25/ORF81 DNA vaccine
investigated the immune protection by using intra-peritoneal (IP)
challenges [20–22]. It was also confirmed that three IM injections are
necessary to ensure significant immune protection and that oral de-
livery of alginate-encapsulated plasmid DNA was not efficacious [23].
Although the ORF25 DNA vaccine strategy is tempting and sometimes
promising, the results obtained in the literature are conflicting. The
discrepancies observed between studies might be partially explained by
differences in the portions of the ORF25 protein used for immunization
(Table 2). In any case, the current method of vaccination (three suc-
cessive IM injections) does not facilitate ease of application in the field.
Furthermore, due to the complexity and high number of glycoproteins
present in the CyHV-3 proteome [24], a single antigenic protein gene
used as a DNA vaccine might not be enough for efficient protection
through different challenge models [23].
4.2. Bacterial vector vaccines
Facing the technical challenges involved with development and
delivering of effective DNA (or subunit) vaccines, some studies have
investigated the potential use of bacteria as vectors for expression of
CyHV-3 antigens. Such bacterial vector vaccines, expressing viral an-
tigens are easily adaptable to large-scale production, and represent ef-
ficient delivery methods. Indeed, many bacterial vaccines can be
adapted to mass vaccination including immersion and sometimes oral
methods. The use of Lactobacillus plantarum expressing CyHV-3 ORF81
(major envelope protein) fused to the glycoprotein G (gG) of spring
viremia of carp virus (SVCV, genus Sprivivirus, family Rhabdoviridae)
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per gram of fish feed. Fish were fed with the vaccine preparation during
three successive days, and for three distinct vaccination periods (a
primary vaccination and two subsequent boosts). Fish were then chal-
lenged by oral administration of either SVCV or CyHV-3. Treated fish
developed specific antibodies against both viruses and were partially
resistant to a lethal challenge. Surprisingly, the serological and survival
data were strikingly similar following the two viral species challenges
(RPS of 63 and 45% for SVCV and CyHV-3 respectively). Also, in a
recent study, the N-terminal (aa 42–149) cysteine-free domain of
CyHV-3 ORF149 (a member of the CyHV-3 ORF25 glycoprotein family),
containing immuno-relevant epitopes [26] was fused to several bac-
terial anchor-motifs. These motifs allowed expression of the viral an-
tigen at the outer bacterial membrane. The plasmid constructs were
transformed into Escherichia coli BL21 and the recombinant bacteria
were used as inactivated bacterial suspensions. The inactivated bac-
terial preparations were delivered by immersion preceded by an un-
conventional low-intensity ultrasound treatment [27]. A serological
response was not observed in all of the common carp and zebrafish
(Danio rerio) vaccinated by this method and unfortunately, the level of
protection against a lethal challenge was not investigated in this study
[27]. However, though still in its infancy, this method represents a
putative promising way to improve CyHV-3 vaccine strategies.
4.3. Inactivated vaccines
Inactivated vaccines consist of the entire pathogen of interest, killed
or inactivated, typically using chemical or physical methods [28]. Due
to their inability to replicate in the host, inactivated vaccines are gen-
erally considered safer, but at the same time, less immunogenic than
live-attenuated vaccines. In aquaculture, inactivated viral vaccines
usually require multiple injections of a high dose of antigens combined
with adjuvants, implying a low cost-benefit balance [29]. Few studies
have investigated the potential use of inactivated vaccines against
CyHV-3. In one such study, formalin-inactivated CyHV-3 viral particles
were trapped within a liposomal compartment and spread onto dry food
pellets. Administered by ingestion, they induced partial immune pro-
tection against a lethal challenge (RPS around 70%) (Table 2) [30].
Another report employing similar methodology with a different CyHV-3
isolate was able to induce similar protection [31].
In another report, three adjuvanted (Montanide ISA 763 A VG) and
inactivated CyHV-3 antigen preparations were tested as vaccine can-
didates, however they showed very limited protection against sub-
sequent viral challenge. This may have been caused by incomplete
presentation of viral antigens, with the administered vaccine persisting
as intact droplets within the abdominal cavity after injection [32].
4.4. Attenuated vaccines
Attenuated vaccines are live viral strains for which the virulence has
been reduced or abolished by serial passages in cell culture (conven-
tional attenuated vaccine) or by targeted viral genome editing (re-
combinant attenuated vaccines). Unlike inactivated, subunit, vector or
DNA vaccines, attenuated vaccines are highly representative of a nat-
ural viral infection in the host. Because of this, they are usually effective
after a single dose administration, and they facilitate much broader
stimulation of the immune system during vaccination, resulting in both
cell-mediated and humoral adaptive immune responses and increased
long-term protection against viral disease. As they usually retain their
natural ability to enter the host without the need of specialized delivery
methods, such vaccine strains should be largely compatible with mass
vaccination in an aquaculture setting (i.e. inoculation of large numbers
of fish via bathing). Given their superior efficacy, historically, atte-
nuated viral vaccines have arguably been the most important and ef-
fective intervention method against the spread of viral disease.
However, given their nature, these vaccines also raise safety concerns,
such as residual virulence, reversion to virulence, and unregulated
spread from vaccinated to naïve subjects.
4.4.1. Conventional attenuated vaccines
A conventional attenuated vaccine has been developed against
CyHV-3 [6,33–36]. KoVax Ltd (Israel) initially developed and com-
mercialized the CyHV-3 conventional attenuated vaccine under the
denomination of KV3. The KV3 vaccine was also temporarily launched
in the US market by Novartis under the denomination of Cavoy.
The development of this vaccine went through different successive
processes. First, a CyHV-3 Israel strain was serially passed in koi fin
cells (>20 passages), leading to partial attenuation of the virus [6].
Second, the viral suspension obtained by serial passages was subcloned
and tested in vivo, leading to the selection a specific subclone [6,34].
Finally, the selected subclone was further treated by UV irradiation
preceding a second and ultimate subcloning step [34]. The main goal of
these different procedures was to (i) to limit the risk of recombination
between variants present in the viral suspension (achieved through
subcloning) and (ii) increase the number of mutations introduced in the
viral genome and therefore decrease the risk of reversion to a virulent
phenotype (achieved through serial passages and UV irradiation). This
vaccine has been tested using several delivery methods that have been
shown to provide protection against a lethal challenge. Importantly, the
current commercialized KV3 vaccine was designed for delivery via
simple immersion of koi and common carp in water containing the
attenuated strain, thereby allowing mass vaccination.
The safety and efficacy profile of this conventional attenuated
vaccine was studied extensively [6,11,15,23,33–37]. Regarding the
safety, several independent trials showed residual virulence in some
circumstances. For instance, the vaccination of small-sized fish (<50 g)
can be associated with clinical signs of the CyHV-3 disease and mor-
talities (10–30% according to the studies, Table 2) [11,35–37]. Fur-
thermore, some mortalities were specifically associated with certain
carp strains [37] or were attributed to a bad health status of the fish
used [35]. Notably, recurrent detection of CyHV-3 DNA was observed
in fish that survived or died from the vaccination [36]. Nevertheless,
field trials were successfully conducted for regulatory purposes in Is-
rael, Indonesia and USA. They indicated that this attenuated strain met
the requirements necessary for registration of the vaccine in these re-
gions [15].
A second important issue associated with this vaccine is the un-
known determinism of the attenuation. It makes it difficult to determine
the likelihood of reversion to a virulent phenotype [15,38]. Sequencing
revealed several mutations (including large insertions and deletions
(indels)) throughout the viral genome [11], but the exact role of these
mutations in the attenuation is completely unknown. If the attenuation
is caused by single nucleotide polymorphisms, these mutations are the
most at risk of reversion during vaccine infections, with resulting re-
vertant viral strains having a competitive advantage. However, back-
passage assays, during which the vaccine strain is recovered from
vaccinated animals and administered to naïve animals successively, did
not show any reversion to virulence [15].
Ecological safety concerns can also be raised when registering live
attenuated vaccines [15]. Indeed, the attenuated vaccine could cause
disease by transmission to fish species which are not the primary target
of the vaccination. Despite the fact that CyHV-3 DNA can be detected in
a variety of fish species (reviewed by Ref. [2]), disease is only diag-
nosed in common and koi carp and related hybrids [39]. Nevertheless,
the susceptibility of additional fish species to CyHV-3 is still highly
controversial [40,41]. However, the possibility that the attenuated
vaccine strain may infect cohabitant common carp not primarily tar-
geted by the vaccination has been investigated [36]. In terms of hor-
izontal transmission of the vaccine strain, no death or signs of disease
were observed in naïve carp cohabited with vaccinated carp at four
weeks post-vaccination. However, unfortunately, quantitative PCR
analysis could not be interpreted confidently due to positive results
obtained in the negative control groups [36]. To the best of our
M. Boutier, et al. Fish and Shellfish Immunology 93 (2019) 531–541
535
knowledge, the ability of the conventional attenuated vaccine to es-
tablish latency and to reactivate have not been demonstrated. Latency
associated with abortive reactivation (without excretion of infectious
particles) could act as periodical boosts of the adaptive immune re-
sponse providing lifelong protection to vaccinated subjects. However,
latency associated with successful reactivation (with excretion of in-
fectious particles) could be associated with uncontrolled spreading of
the vaccine strain and could enhance the occurrence of recombination
between the vaccine strain and field strains.
Regarding the efficacy, the attenuated vaccine has shown satisfying
results, inducing RPS ranging from 80 to 100%. Importantly, in these
experiments, fish were challenged by cohabitation with sick fish in
several studies, which represents a highly relevant challenge method.
Following vaccination, detection of anti-CyHV-3 antibodies started
between 7 and 14 days post-infection (dpi), and increased until 20–40
dpi and finally progressively decreased with significant titers still de-
tected at 150 dpi [6,35]. During these periods, the anti-CyHV-3 anti-
body response correlated with protection against CyHV-3 disease. On
the other hand, at 280 dpi, the titer of anti-CyHV-3 antibodies in pre-
viously vaccinated fish was only slightly higher or comparable to that of
naive fish. Nevertheless, immunized fish, even those in which anti-
bodies were no longer detectable, were resistant to a lethal challenge,
possibly because of the subsequent rapid response of B and T memory
cells to antigen re-stimulation [35]. Similarly, anti-CyHV-3 antibodies
were detected in only 14% of the vaccinated fish 13 months post-vac-
cination, however this was associated with only a partial protection
against a lethal challenge, supporting the need of annual booster vac-
cination [33]. Indeed, following booster vaccination performed 6
months after initial exposure to the attenuated vaccine, antibody titers
increased again [35].
4.4.2. Recombinant attenuated vaccines
Due to scientific advances in molecular biology and molecular vir-
ology, the development of attenuated vaccines is evolving away from
the historical empirical approaches and towards rational design. Using
this approach, a viral genome can be edited to delete genes encoding
virulence factors in such a way that reversion to virulence can be ex-
cluded.
The initial cloning of the CyHV-3 genome as infectious bacterial
artificial chromosome (BAC) facilitated viral editing using prokaryotic
mutagenesis methods [42]. This is referred to as BAC cloning and the
main advantage of this approach, over viral editing using homologous
recombination in eukaryotic cells, is the high stability of the viral
genome throughout the process. This method, combined with the ad-
vances in DNA sequencing, allows rapid generation, characterization
and comparison of viral recombinants mutated only for the desired
ORFs.
Recombinant CyHV-3 attenuated vaccine candidates have been
generated by targeting different genes thought to encode virulence
factors. Initially, several studies investigated the potential use of viral
recombinants deleted for genes encoding for enzymes of the nucleotide
metabolism (ORF55 encoding for a thymidine kinase (TK), ORF123
encoding a deoxyuridine triphosphatase (dUTPase), and ORF141 en-
coding for the large subunit of the ribonuleotide reductase (RNR)).
Deletion of the RNR ORF141 gene led to a drastic reduction of viral
growth in vitro. Truncation of the TK ORF55 was initially found to
partially attenuate the virulence [42], but the attenuation was weak
and not reproducible between trials [43,44]. Similarly, the ORF123
dUTPase deletion is associated with partial attenuation. Recently, using
an eukaryotic recombination based approach, a double deletion of both
ORF55 TK and ORF123 dUTPase has been described in two in-
dependent viral strains (CyHV-3 I, low cell culture adaptation/high
virulence profile [45]; and CyHV-3 T, high cell culture adaptation/low
virulence profile [11,13]) [46]. In both cases, an important attenuation
was observed, and significant protection was ensured following a lethal
challenge with the parental strain (Table 2) [46]. The use of the CyHV-3
T viral strain has two main advantages (i) an attenuated genetic
background, possibly due to serial passages in cell culture and (ii) an
efficient viral growth in vitro ensuring a good vaccine production.
However two disadvantages of this design include (i) the CyHV-3 T
determinism of attenuation is unknown and (ii) multiple and distant
deletions increase the risk of emergence of single deleted recombinants
for either of the two ORFs following recombination with wild type
strains. These recombinants carrying one of the two genetic traits of the
vaccine should benefit from a partial gain of virulence. Their possible
spread from vaccinated subjects to cohabitants could be confused with
vaccine spread unless the follow-up will be based on the study of both
deleted loci.
The prokaryotic approach described earlier was also used to target
and remove CyHV-3 envelope glycoproteins [24]. The 16 predicted
virion transmembrane proteins (VTPs) were deleted by using the BAC
cloning mutagenesis technology. Individual deletion of 8 VTPs en-
coding ORFs was compatible with viral growth. Among them, only
deletions of ORF148 and ORF25 (both members of the ORF25 family),
were associated with slight or severe attenuation, respectively. Un-
fortunately, deletion of ORF25 was safe but not efficacious in protecting
fish against a lethal challenge (maximum RPS of 34%) [24]. Similarly,
another study investigated the single deletion of ORF148 or ORF149,
and the combinational deletion of both [47]. Again, the attenuation
obtained was only partial with approximately 50% and 40% reduction
of the virulence observed for single and double deleted mutants re-
spectively compared to the parental strain (CyHV-3 T) [47]. ORF25,
ORF148 and ORF149 (together with ORF27, ORF65 and the pseudo-
gene ORF26) are members of the ORF25 family, all encoding VTPs.
While studies such as the ones described earlier indicate that the de-
letion of these genes can cause attenuation, it should be acknowledged
that recombinants displaying single (or even double) deletions for
members of this glycoprotein family are always open to the risk of re-
version to virulence through mutation of the remaining paralogous
genes, making them less suitable vaccine candidates.
In another series of studies, a vaccine candidate was produced by
taking advantage of an accidental double deletion of ORF56 and ORF57
obtained following a non-homologous recombination event [43]. The
ORF56-57 deletion (Δ56-57) was replicated in several independent re-
combinants, using BAC cloning mutagenesis (CyHV-3 FL viral strain).
They were all compatible with its use as an attenuated recombinant
vaccine for mass vaccination of carp by immersion in water containing
the virus. Indeed, vaccination of common carp with the Δ56-57 strain
was particularly safe and induced high protection against a lethal co-
habitation challenge. The safety was demonstrated for young and small-
sized fish (mean weight of 1.3 g; 4 months old) [43]. Importantly, the
immune protection was similar against a homologous (CyHV-3 FL
strain, moderate virulence, European lineage) and heterologous chal-
lenge (CyHV-3 M3 strain, high virulence, Asian lineage) (Table 2)
[11,14,43]. Interestingly, the safety and efficacy investigations of this
vaccine candidate were not limited to the clinical outcome of the dis-
ease. Regarding the safety, the Δ56-57 locus was combined with a lu-
ciferase (Luc) expression cassette described previously [48], forming
the Δ56-57 Luc viral recombinant [43]. This was exploited to in-
vestigate the vaccine tropism and transmission using In Vivo Biolumi-
nescent Imaging System (IVIS). The results obtained showed that the
vaccine candidate replicated at the skin portal of entry for 8 days fol-
lowing vaccination, suggesting good immune stimulation at the skin
mucosa. In the secondary sites of infections, the vaccine replication was
delayed, of lower intensity, and present for a shorter duration compared
to the wild type infection. Histopathological analyses of the gills
showed minimal lesions induced by the vaccine and a complete mid-
term histological recovery. Regarding transmission, vaccinated fish
were cohabited (allowing direct or indirect transmission) with naïve
sentinel fish immediately following vaccination, i.e. to maximise the
chances of transmission. Indirect transmission of the vaccine strain was
not observed (i.e. through infectious water), while a limited and erratic
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transmission was observed when vaccinated and sentinel fish were
mixed together in the same tank allowing transmission through in-
fectious water and through fish skin-to-skin contacts. Although the
ability of the Δ56-57 vaccine to establish latency and reactivation is
unknown, its limited replication and transmission during the acute in-
fection of naïve subjects makes it unlikely that it will efficiently re-
plicate in an immunized subject following a hypothetical reactivation
event. Finally, the protective immune response following vaccination
was shown to block the challenge viral infection at the skin portal of
entry [43]. Whether this protection is the consequence of a mucosal
adaptive immune response or not remains to be determined. This
homologous virus/fish model represents a unique opportunity to study
fish mucosal immunity in the context of vaccination. Recently, ORF57
was found to be the crucial virulence factor in the double deletion of
ORF56 and ORF57. The function of ORF57 remains to be determined,
but ORF57 protein is an abundant component of the virion structural
proteome [24,49]. Interestingly, this opens the opportunity to use this
vaccine as a DIVA strategy (Differentiating Infected from Vaccinated
Animals), on the basis that an adaptive serological immune response
could be raised against ORF57 protein following a wild type infection,
but not after vaccination. The immunogenicity of ORF57 protein, but
also of dUTPase and TK proteins described above, are currently un-
known. Also, a monoclonal antibody raised against ORF57 protein is
already available, allowing the differentiation between the vaccine
strain and the wild type strains [14]. Finally, the identification of
ORF57 as a crucial virulence factor of CyHV-3 opens new vaccine re-
search opportunities, as ORF57 homologs represent evident targets for
further development of attenuated recombinant vaccines for other pa-
thogenic viruses (CyHV-1, CyHV-2 and anguillid herpesvirus 1 (AngHV-1);
all members of the genus Cyprinivirus, family Alloherpesviridae) [14].
5. Knowledge gained from vaccine studies on other
alloherpesviruses
The family Alloherpesviridae consists of a growing list of allo-
herpesviruses infecting fish and amphibians. It contains four genera
with 13 virus species currently recognised by the International
Committee on Taxonomy of Viruses (ICTV). Multiple vaccine candi-
dates against alloherpesviruses have been developed but very few are
currently commercially available. Inactivated vaccine candidates
against CyHV-2 (a virus phylogenetically close to CyHV-3) have been
explored. These include formalin- or beta-propiolactone- inactivated
CyHV-2 preparations which were injected IP to goldfish (Carassius
auratus) or gibel carp (Carassius gibelio), respectively and induced par-
tial protection against a lethal challenge (RPS 42–63% and 71%, re-
spectively) [50,51]. The results obtained for this CyHV-2 inactivated
vaccine are promising in terms of safety/efficacy balance. Nevertheless,
this vaccination method still suffers several drawbacks: (i) the high
volume of crude supernatant needed to vaccinate each fish, (ii) the
necessity to individually handle and inject the fish and (iii) the relative
low immune protection obtained even when boosting strategies were
applied [50,51]. Subunit vaccines consist of a reduced and specifically
selected portion of the virus antigen repertoire. Subunit vaccines
against CyHV-2 have been tested in gibel carp. This involved im-
munization with secreted forms of the ORF25, ORF25C and ORF25D
antigens (CyHV-2 ORF25 glycoprotein family) purified from yeast (Pi-
chia pastoris). This led to partial protection (RPS: 54%-75%) [52]. This
method has the added advantage of being compatible with mass and
low cost production of the antigen of interest through purification from
the supernatant of cultivated yeasts [52].
Some DNA vaccines against Ictalurid herpesvirus 1 (IcHV-1, also
known as channel catfish virus or CCV, genus Ictalurivirus) have also
been tested. Injectable DNA vaccines against IcHV-1 showed ambiguous
results, even when a cocktail of plasmids encoding multiple ORFs were
used [53,54]. Vaccination with plasmids encoding ORF6, ORF59 (en-
coding for a membrane protein and a VTP respectively) or the
combination of both, induced significant protection against IcHV-1
challenge [53], but that result was not reproduced elsewhere [54]. DNA
immunization with ORF1, ORF3 (encoding immediate-early unknown
proteins), ORF7, ORF8, ORF10, ORF19, ORF46, ORF51 (encoding
membrane proteins) and ORF53 (encoding capsid proteins) did not
induce immune protection against a lethal challenge [53,54]. Im-
portantly, cocktails of up to 11 DNA plasmids (1 μg/plasmid) did not
enhance immune protection. Along with other studies on the use of
DNA vaccines against other alloherpesviruses, this highlights the fact
that selecting the most relevant antigens for immunization is one of the
main challenges for future research.
Conventional and recombinant attenuated vaccines have also been
developed against IcHV-1. A conventional attenuated vaccine was
generated through serial passage of the Auburn IcHV-1 strain on a
walking catfish cell line (Clarias Batrachus) [55]. The parental strain,
that had a history of 35 passages, was further passed 60 times in cell
culture (from then referred to as the V60 strain). A dose-effect study
showed a high safety of the attenuated strain following IP injection with
up to 1×105 TCID50 per fish. The definitive cause of attenuation of
the V60 strain is still unknown, despite the fact that a deletion of ORF50
(encoding a putative secreted glycoprotein) was detected [56]. A re-
combinant attenuated vaccine candidate was also developed against
IcHV-1 by deletion of the TK gene (ORF5) which resulted in a 100 fold
decrease in virulence. Vaccination by immersion with this vaccine
candidate at the doses of 3× 104 and 3×105 had a safety/efficacy
profile of 0/60% and 5/100%, respectively [57]. Deletion of TK from
different alloherpesvirus models seems to be definitely associated with
attenuation in some conditions [42,46,57]. On the other hand, some
discrepancies were observed between trials [43,44] and single deletion
of the TK was not always sufficient to induce attenuation of the virus
[47]. TK deletion is thought to mainly affect the replication of the virus
in non-replicating cells that do not provide endogenous expression of
cellular TK (a cellular enzyme expressed during the S phase of the cell
cycle). However, infection of fish in their fast growth phase could ex-
press high level of cellular TK in replicating cells, thereby facilitating
the complementation of the TK viral defect [42,57]. This suggests that
the effect of TK deletion on viral replication could be dependent of the
physiology of the host with attenuation being observed mainly in fish
with reduced cell division. Taking into account that small fish asso-
ciated with a high proportion of dividing cells are those to be vacci-
nated, deletion of TK does not appear to be a good gene candidate for
virus attenuation.
Huge improvements in molecular techniques and viral genome
manipulation created opportunities to develop viral vectors that act as
expression platforms for antigens from other pathogens. Preliminary
results obtained from inoculating fish with a TK deleted, IcHV-1 atte-
nuated vaccine expressing a recombinant LacZ reporter gene showed
that immunized fish expressed the LacZ reporter and indeed developed
an antibody response against the transgene. Interestingly, this ser-
ological adaptive immune response could be boosted 20 days post-
vaccination. The previous cloning of IcHV-1 as an infectious bacterial
artificial chromosome [58] allows manipulation of this vial genome in a
similar manner to CyHV-3 [42], and thus is a crucial tool in the de-
velopment of future innovative vaccines against IcHV-1.
6. Future prospects for CyHV-3 vaccine development
Ongoing advances in our understanding of fish immunology and
constant progression in vaccine technology will continue to play a role
in shaping the future of CyHV-3 vaccine development. As with all
vaccines, there will continue to be a drive to develop vaccines with
superior safety/efficacy profiles and improved delivery methods.
Furthermore, vaccines for fish, and other animals in the food produc-
tion sector in general, are under additional constraints in order to
maximise their use in the field. Firstly, ideally the vaccine must be
compatible with mass vaccination. Secondly, the cost-benefit ratio
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should be as low as possible, implying the lowest cost for vaccine
production and administration per individual. Thirdly, the use of any
such vaccine should be safe and result in close to 100% RPS. These
constraints will continue to represent the benchmark in determining
whether or not future vaccine approaches may be considered viable
options. In terms of CyHV-3, with the exception of attenuated vaccines,
no approach to vaccination against this virus has met all of the con-
straints described above, these shortfalls and future prospects for fur-
ther development are discussed in the following section. A summary
of the main advantages and disadvantages of some vaccines against
CyHV-3 is provided in Table 3.
6.1. Future prospects on CyHV-3 vaccines based on selected antigens
6.1.1. DNA vaccines
While some DNA vaccine-based approaches have shown promise
[20–22], these involved delivery through IM injection, which is not
suitable to mass vaccination of small-sized common carp. This may be
more suitable to individual vaccination of koi carp, however the risk of
injury to extremely valuable subjects may somewhat limit its use in this
niche sector. The development and refinement of oral or immersion-
based delivery methods may improve the future prospects of DNA
vaccines against CyHV-3 compatible with mass vaccination. While en-
capsulation of CyHV-3 DNA vaccine in alginate for the purposes of oral
delivery did not yield promising results [23], other DNA vaccine en-
capsulation methods may prove useful in facilitating successful oral
delivery. Examples of alternative encapsulation methods for oral de-
livery include the use of chitosan-based nanoparticles, which have
shown promise with DNA vaccines against sea bass nodavirus [59]. In
addition, encapsulation or surface adsorption of DNA vaccines to poly-
(D,L-lactic-co-glycolic)-acid (PLGA) particles may also be potentially
useful for these purposes, if adapted appropriately [19,59,60]. If such
approaches could be used in oral delivery with similar or greater pro-
tection than injection, it may make CyHV-3 DNA vaccines more
compatible with mass vaccination.
6.1.2. Bacterial vector vaccine
The CyHV-3 bacterial vector vaccines are, by their nature, compa-
tible with mass vaccination, being delivered via both by immersion
[27] or orally [25]. However, of those developed, one did not give
impressive survival rates upon challenge [25] and the efficacy for the
other was not investigated – although notably, with the latter, the an-
tibody response to the vaccine was neither high nor consistent [27]. A
common factor with both of these vaccines is that they are based on
prokaryotic vectors. This may have important consequences with re-
gard to correct folding and post-translational modifications of the viral
antigens. Notably, the CyHV-3 antigens used were ORF149 [27] and
ORF81 [25]. ORF149 is a glycoprotein [61], which may be dependent
on post-translational modifications for correct folding. In the case of
ORF149, only the fragment consisting of the N-terminal cysteine-free
domain was included in the vaccine, on the basis that it should not rely
on post-translational modification [27], however the folding of the
truncated versus non-truncated forms was not investigated. Conversely,
the whole ORF81 gene was used in the other vector vaccine described
[25]. While evidence indicates that ORF81 does not undergo extensive
post-translational modification [62], it cannot be ruled out at this stage.
In addition, in this case, CyHV-3 ORF81 was expressed as a fusion
protein with SVCV gG, which may also have had an impact on correct
folding [25]. Thus, the use of prokaryotic systems may have had im-
portant implications with regard to the efficacy of these bacterial vector
vaccines when using viral antigens, and this aspect may need to be
considered with any future CyHV-3 vector-antigen combinations. On
this note, it was recently demonstrated that a eukaryotic vector system
utilizing yeast (Pichia pastoris) could be used in the delivery of GFP to
the epithelium and lamina propria of both the first and second intestine
segments in common carp [63], indicating its potential use as part of
new CyHV-3 vector vaccines. Furthermore, the same yeast species has
also been used in the production of CyHV-2 subunit vaccine
Table 3
Advantages and disadvantages of various vaccines against CyHV-3.
Vaccinea Vaccine type Advantages Disadvantages
ORF25 (ORF81) plasmid- based
vaccines
DNA vaccine - Non-infectious: high safety
- Easy to produce in prokaryotic cells
- ORF25 glycoprotein is a major antigen
- DIVA
- Conflicting results of efficacy between independent
studies
- Requires multiple IM injection to be efficacious
- Risk of integration into the host genome
- Exposure to only specific antigen
Liposome encapsulated CyHV-3
antigens
Inactivated vaccine - Non-infectious
- Compatible with oral vaccination
- Contains all CyHV-3 antigens
- Risks associated with inefficient inactivation
- Partial protection observed against a lethal challenge
- Requires complex lab procedures and high amounts of viral
antigen
KV3 (KoVax Ltd) Conventional attenuated
vaccine
- Vaccine mimicking a natural infection
- Safety/efficacy profile favorable, but not
optimal
- Compatible with mass vaccination
- Differentiation of vaccine and wild type strains
based on analysis of indels
- Residual virulence for small-sized fish
- Determinism of attenuation unidentified
- Risk of reversion to virulence
- Requires environmental temperatures compatible with
vaccine replication
CyHV-3-T ΔDUT/TK Recombinant attenuated
vaccine
- Vaccine mimicking a natural infection
- Good safety/efficacy profile
- Compatible with mass vaccination
- Limited risk of reversion to virulence
- DIVA based on deleted gene (genetically,
antigenically and hypothetically based on
serology)
- Requires environmental temperatures compatible with
vaccine replication
- Risk of recombination in between the two genomically
distant deletions, thereby producing single deleted
recombinants
- Considered as a genetically modified organism by
regulation authorities
CyHV-3-FL Δ56-57 Recombinant attenuated
vaccine
- Vaccine mimicking a natural infection
- Good safety (including reduced spreading)/
efficacy profile
- Compatible with mass vaccination
- Limited risk of reversion to virulence
- DIVA based on deleted gene (genetically,
antigenically and hypothetically based on
serology)
- Requires environmental temperatures compatible with
vaccine replication
- Considered as a genetically modified organism by
regulation authorities
a Only vaccines (or candidate vaccines) displaying a promising safety/efficacy profile are shown in this table.
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components and showed moderate-high survival rates in gibel carp
[52].
6.1.3. Antigen selection
With regard to DNA, subunit and bacterial vector vaccine devel-
opment, the choice of antigen is a crucial aspect. There have only been
a few studies into immunological relevance of specific CyHV-3 proteins
[26,61,62,64] and they have arbitrarily focused on putative viral en-
velope and capsid proteins including ORF25, ORF65, ORF81, ORF84,
ORF92, ORF99, ORF136, ORF138, ORF146, ORF148, and ORF149.
These studies have had an important influence on the antigen choices
made in the following vaccine studies [20–23,25,27]. However,
CyHV-3 has a complex proteome with 34 structural virion proteins
consistently detected [2,24,49,65]. Vaccine strategies may require the
use of several different types of relevant viral antigen in order to induce
sufficient protection. Thus, efforts to increase the amount of known
immunologically relevant structural proteins will remain an important
element in the future of CyHV-3 vaccine design. Furthermore, there
may be many non-structural viral proteins that may be important in
terms of major histocompatibility complex (MHC) Class I display to
cytoxic T-cells as part of cell mediated adaptive immunity. The iden-
tification of such proteins may represent important steps towards the
development of vaccines comprising viral antigens relevant to both
major arms of the adaptive immune response.
6.2. Future prospects on CyHV-3 vaccines based on whole viral particles
6.2.1. Inactivated vaccines
CyHV-3 inactivated vaccine prototypes were intrinsically primed for
mass vaccination using the oral route [30,31]. Both inactivated CyHV-3
vaccines described here utilize liposome encapsulation for oral de-
livery. While the results are encouraging, they also highlight some ef-
ficacy issues [30,31], however the use of adjuvants (see section 6.3)
may help overcome this. In addition, other encapsulation methods used
with other inactivated viral vaccines for example, PLGA encapsulation
of inactivated viral haemorrhagic septicaemia virus (VHSV) for delivery
to olive flounder, have also facilitated delivery and protection via both
immersion and oral routes [66].
6.2.2. Attenuated vaccines
By far, the best performing CyHV-3 vaccines are the attenuated
vaccines. Crucially these vaccines meet all of the three main criteria set
out at the beginning of this section. Future research into CyHV-3 atte-
nuated vaccines is likely to revolve around the identification of dele-
tions that provide enhanced safety/efficacy profiles. There are two
types of attenuated CyHV-3 vaccine: (i) conventional attenuated vac-
cine: designed empirically, through a combination of repeated serial
passaging in vitro and UV irradiation [34] and (ii) recombinant atte-
nuated vaccine: developed through rational mutagenesis of the viral
genome associated with attenuation [43,46]. Both types were described
in more detail in section 4 of this review. However, in terms of safety,
the rationally designed vaccines are far superior for 3 key reasons. First,
the determinism of the attenuation is known in the recombinant atte-
nuated vaccines, but not in the conventional attenuated vaccine. While
the conventional attenuated vaccine displays indels and point muta-
tions, it is unclear which one(s) of them is (are) responsible for the
attenuation. A single change in one crucial mutation for attenuation
may cause reversion to virulence, making it difficult to conduct valid
risk assessment on its use in the field. Secondly, the reversion of the
rationally designed recombinant attenuated vaccines through recovery
of an entire deleted gene is only possible by co-infection with a viral
strain providing the missing gene, i.e. the same cells would need to be
simultaneously infected with a wild type viral strain. Given the nature
of the genetic changes responsible for attenuation, the chances of a
rationally designed attenuated strain reverting to virulence are much
lower. Thirdly, the absence of specific genes in the rationally designed
strains greatly facilitates a more robust DIVA strategy, allowing sur-
veillance and establishment of viral eradication plans. In summary,
compared to conventional attenuated vaccine, the superior safety of the
rationally designed vaccines is self-evident, and it is difficult to present
convincing and rational argument to the contrary. Interestingly, the
regulatory authorities in three countries have approved the use of the
CyHV-3 conventional vaccine (USA, Indonesia and Israel) [15]. Given
their superior safety, it is logical to conclude that such precedents
should only act to strongly support the registration of recombinant at-
tenuated vaccines that are currently under development. However, in
some countries regulation authorities are still considering recombinant
attenuated vaccines as genetically modified organisms and apply more
restrictive rules for registration.
6.3. Mucosal immunity and future prospects for the study of the immune
response induced by vaccines
As the evidence indicates above, a push towards oral and immersion
delivery will be a crucial part of the future direction of CyHV-3 vac-
cines. Not only is this more compatible with mass vaccination, it also
facilitates entry and/or immune stimulation at mucosal surfaces.
Mucosa-associated tissues of teleost fish such as skin, gills and intestine
play crucial roles in protection against pathogens [43,67–69]. Thus, the
central aim of teleost vaccination should ideally be to induce mucosal
immunity in one or more mucosal surface(s) (i.e. gut, skin, gills) leading
to subsequent stimulation of a systemic protection across all mucosal
barriers. This makes oral or immersion delivery, an attractive option for
any fish vaccine. However, the occurrence of tolerance on mucosal
surfaces may be an obstacle, particularly where repeat/boost vaccina-
tion regimes are necessary. The ability to gain tolerance at mucosal
surfaces is important in avoiding immune reactions to beneficial com-
mensals [68]. Mucosal vaccination could in some circumstances also
induce tolerance against the vaccine antigens. This phenomenon has
been demonstrated for the gut mucosa after oral delivery of antigens
[60], including in carp [70]. This is referred to as “oral tolerance”, and
while it may not be unique to the gut, an equivalent phenomenon has
not been yet described with other fish mucosal surfaces, indicating that
the gut mucosal surfaces are possibly more prone to this. Finally, the
oral route has one additional drawback. The dose of vaccine received by
each fish depends on its appetite and so is not homogeneous between all
fish, which may of course affect efficacy results.
This suggests that immersion-based delivery may be less proble-
matic. Of the vaccine formats described, attenuated CyHV-3 vaccines
are the most suited to immersion-based delivery. The skin of carp has
been shown to act as the major portal of entry for CyHV-3 wild type
virus and the Δ56-57 recombinant vaccine [43]. Moreover, it was de-
monstrated that the skin is the major site of viral replication of the
attenuated strain following vaccination by immersion in water con-
taining the virus. It is likely that the replication and immune stimula-
tion at this important mucosal surface ultimately explains the protec-
tion observed against subsequent viral challenge [43]. Interestingly,
CyHV-3 was also shown to infect carp through infection of the peri-
odontal pharyngeal mucosa when administered through contaminated
food pellets [71]. Therefore, it may be feasible to also deliver this
Δ56-57 recombinant attenuated vaccine via the oral route through in-
gestion of spiked food pellet. Thus, this attenuated strain may also re-
present an important research tool, providing an opportunity to in-
vestigate immune responses to a recombinant attenuated vaccine at
multiple mucosal surfaces.
6.4. Future prospects on use of adjuvants
The use of adjuvants may also be a key feature in increasing the
efficacy of CyHV-3 vaccines. To date, their inclusion in CyHV-3 ex-
perimental vaccine formulation has been limited and has shown no real
success [22,32]. However, vaccines developed against other fish
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pathogens have included immunostimulants such as beta-glucans,
polyinosinic polycytidylic acid (poly I:C), CpG [72], many of which
may be tested and exploited in future experimental CyHV-3 vaccines.
The choice of adjuvant is known to have a significant impact on vaccine
performance [73], not only by simply enhancing the immune response,
but also by guiding the type of adaptive response that should be de-
veloped [74,75]. Like viruses of other vertebrates, complete clearance
of CyHV-3 may also rely on the polarization towards T-helper-1 (Th1)
response, although this still needs to be fully investigated. As knowl-
edge grows, future adjuvant selection for CyHV-3 vaccines may be
based on those known to stimulate the appropriate adaptive immune
response. Getting to this point will also require the generation of more
data on specific cytokine profiles displayed by carp in response to a
range of different adjuvants, and thus this represents a key field or
research for future development.
6.5. Future prospects on CyHV-3 vaccine testing and harmonization
In CyHV-3 vaccine studies described in this review, there are a
variety of wild type viral strains used and ways in which carp are
challenged with those viral strains after vaccination. These include: (i)
direct application of virus to gills [30,31], (ii) IP injection [20–22,32],
(iii) bath/immersion [23,33,36,46], (iv) feeding/oral [25], and (v)
cohabitation with clinically infected fish [14,23,34,43]. Out of these
methods, cohabitation is the most representative of a natural infection
and may be the most valid form of challenge post-vaccination. How-
ever, some critics and concerns can be raised against this method of
challenge. First, the variability of virus excretion by shedder fish could
be the source of experimental variabilities. Second, this approach re-
quires additional subjects for which the application of ending points is
problematic leading to ethics concerns. Of note, challenge through
bath/immersion and cohabitation have been shown to reveal different
levels of protection [23]. In the quoted study, protection was only ob-
served after immersion challenge but not after cohabitation. Therefore,
in order to derive meaningful conclusions, where possible, it may be
prudent for future CyHV-3 vaccine studies to include cohabitation
challenge as part of the experimental design.
7. Conclusion
We can learn a lot from the studies that have been conducted into
the development of CyHV-3 vaccines. However, currently there are
certain knowledge gaps in terms of antigen selection, delivery me-
chanisms and adjuvant impact. Thus, there is tremendous scope for new
innovation in the design, application and enhancement of CyHV-3
vaccines. Continued scientific progression and expansion of knowledge
together with continued engagement with authorities on appropriate
regulatory framework are aspects that will be instrumental in control-
ling the economic impact of this devastating virus.
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